Wockhardt Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Latest quarter profit grew 199.1% YoY, showing strong momentum
- Operating margins have improved to 16.1% from 5.2%
- Company generates healthy free cash flow
- Company maintains a comfortable, low leverage position
CONS
- A large part of profit comes from other income (57.6% of PBT)
- Company has a low return on equity of -3.8% over last 3 years
- Company has a low return on capital employed of 2.9%
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -1.78x)
- Promoter holding has decreased over last 2 years: -2.9pp
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1868.50 | 37.06 | 448315.74 | 0.86 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9482.75 | 86.06 | 251737.22 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4931.90 | 86.01 | 187593.62 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1129.00 | 24.95 | 112618.18 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1368.00 | 32.79 | 110515.04 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1933.25 | 95.54 | 104455.86 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1690.00 | 26.19 | 97238.86 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2092.00 | 17.30 | 95660.02 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1143.20 | 29.61 | 95420.61 | 0.70 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2266.00 | 45.82 | 93596.02 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2439.55 | 38.29 | 68850.12 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| WOCKPHARMA | 2251.55 | 89.45 | 36585.92 | 0.00 | 107.00 | 199.07 | 929.00 | 25.88 | 6.79 | 20.67 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 644 | 753 | 701 | 700 | 739 | 809 | 721 | 743 | 738 | 782 | 888 | 965 | 929 | |
| 628 | 681 | 664 | 803 | 648 | 699 | 593 | 679 | 666 | 604 | 711 | 740 | 844 | |
| Operating Profit | 16 | 72 | 37 | -103 | 91 | 110 | 128 | 64 | 72 | 178 | 177 | 225 | 85 |
| OPM % | 2.48% | 9.56% | 5.28% | -14.71% | 12.31% | 13.60% | 17.75% | 8.61% | 9.76% | 22.76% | 19.93% | 23.32% | 9.15% |
| 0 | 24 | 8 | 54 | 30 | 9 | 8 | 15 | -77 | 21 | 15 | 67 | 31 | |
| Interest | 79 | 76 | 77 | 73 | 73 | 73 | 60 | 48 | 48 | 55 | 60 | 50 | 52 |
| Depreciation | 55 | 55 | 55 | 58 | 54 | 55 | 55 | 53 | 56 | 53 | 65 | 53 | 55 |
| Profit before Tax | -118 | -35 | -87 | -180 | -6 | -9 | 21 | -22 | -109 | 91 | 67 | 189 | 116 |
| Tax % | -15.25% | -108.57% | 1.15% | 1.67% | -166.67% | -77.78% | 4.76% | -104.55% | 0.92% | 9.89% | 8.96% | 13.23% | 7.76% |
| Net Profit | 0 | 0 | 0 | 0 | -16 | -16 | 20 | -45 | -108 | 82 | 61 | 164 | 107 |
| -9.28 | -5.37 | -5.75 | -11.64 | -0.95 | -1.47 | 0.91 | -1.57 | -5.53 | 4.81 | 3.61 | 10.23 | 6.55 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4,015 | 3,937 | 3,566 | 2,844 | 2,708 | 3,230 | 2,651 | 2,798 | 3,012 | 3,373 | 3,564 | |
| 4,002 | 3,992 | 3,604 | 2,746 | 2,771 | 2,932 | 2,550 | 2,759 | 2,619 | 2,747 | 2,899 | |
| Operating Profit | 13 | -55 | -38 | 98 | -63 | 298 | 101 | 39 | 393 | 626 | 665 |
| OPM % | 0.32% | -1.41% | -1.08% | 3.44% | -2.33% | 9.23% | 3.81% | 1.39% | 13.05% | 18.56% | 18.66% |
| 114 | -181 | 21 | 60 | -10 | -163 | -172 | 69 | 62 | 52 | 134 | |
| Interest | 225 | 255 | 265 | 276 | 249 | 299 | 302 | 305 | 254 | 213 | 217 |
| Depreciation | 149 | 150 | 164 | 224 | 246 | 247 | 251 | 223 | 217 | 227 | 226 |
| Profit before Tax | -247 | -641 | -447 | -342 | -568 | -411 | -624 | -420 | -16 | 238 | 463 |
| Tax % | 8.54% | -4.01% | 30.18% | 59.67% | 47.71% | 32.12% | 0.48% | -12.38% | -256.25% | 16.39% | 10.58% |
| Net Profit | -226 | -667 | -312 | -138 | -297 | -279 | -621 | -472 | -57 | 199 | 414 |
| EPS | -17.71 | -55.01 | -17.58 | -6.25 | 56.88 | -20.24 | -38.79 | -30.06 | -2.90 | 13.15 | — |
| Dividend Payout % | -56.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- -3%
- 5 Years:
- 4%
- 3 Years:
- 8%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- -2%
- 5 Years:
- -21%
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- 11%
- 5 Years:
- 42%
- 3 Years:
- 106%
- 1 Year:
- 42%
RETURN ON EQUITY
- 10 Years:
- -9%
- 5 Years:
- -7%
- 3 Years:
- -4%
- Last Year:
- 4%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 55 | 55 | 55 | 55 | 55 | 72 | 72 | 77 | 81 | 81 |
| Minority Interest | 382 | 346 | 330 | 386 | 383 | 353 | 308 | 303 | 304 | 341 |
| 3,244 | 2,760 | 2,587 | 2,586 | 3,293 | 3,759 | 3,266 | 3,269 | 4,261 | 4,846 | |
| 3,853 | 2,610 | 2,453 | 2,451 | 1,848 | 1,808 | 1,858 | 1,965 | 1,868 | 2,073 | |
| Trade Payables | 534 | 602 | 840 | 895 | 696 | 921 | 867 | 766 | 592 | 563 |
| 780 | 1,605 | 1,305 | 1,375 | 1,101 | 757 | 704 | 690 | 480 | 234 | |
| Total Liabilities | 8,849 | 7,978 | 7,571 | 7,749 | 7,376 | 7,670 | 7,075 | 7,070 | 7,586 | 8,138 |
| 2,773 | 2,888 | 3,058 | 3,502 | 3,343 | 3,462 | 3,042 | 2,881 | 2,736 | 2,791 | |
| Capital Work in Progress | 971 | 1,039 | 900 | 836 | 603 | 389 | 414 | 434 | 513 | 671 |
| 563 | 214 | 0 | 0 | 0 | 0 | 0 | 0 | 422 | 412 | |
| 1,108 | 856 | 819 | 716 | 799 | 769 | 658 | 640 | 725 | 887 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 618 | 661 | 588 | |
| Cash & Bank | 1,604 | 1,082 | 449 | 268 | 292 | 406 | 124 | 529 | 191 | 250 |
| 1,831 | 1,900 | 2,345 | 2,426 | 2,339 | 2,644 | 2,837 | 1,968 | 2,338 | 2,539 | |
| Total Assets | 8,849 | 7,978 | 7,571 | 7,749 | 7,376 | 7,670 | 7,075 | 7,070 | 7,586 | 8,138 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -241 | 86 | 224 | 666 | -170 | 510 | 164 | 219 | -22 | 390 | |
| Cash from Investing | -687 | 630 | 95 | -156 | 1,470 | -201 | -125 | -137 | -783 | -241 |
| Cash from Financing | 1,254 | -769 | -776 | -680 | -1,171 | -71 | -315 | 334 | 409 | -54 |
| 298 | -71 | -499 | -186 | 12 | 141 | -287 | 416 | -396 | 95 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-08-25 - In terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ( Listing Regulations ), we wish to inform you that the Company is in receipt of an Adjudication Order passed by the Commissioner of Customs, Nhava Sheva-II, JNCH.
2026-08-25 - Pursuant to Regulation 30 read with Schedule III part A para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the newspaper advertisement published today i.e 25th August, 2026, regarding the opening of special window for re-lodgement of the transfer requests of shares held in physical form.
2026-08-10 - Disclosures relating to the 27th Annual General Meeting of Wockhardt Limited held on 10th August, 2026: A) Proceedings of the 27th AGM B) Scrutinizers Report on Voting Results of 27th AGM and C) Voting Results of 27th AGM.
2026-08-10 - Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173A of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed Monitoring Agency Report towards utilization of proceeds of Qualified Institutions Placement ( QIP ) for the quarter ended June 30, 2026, issued by CRISIL Ratings Limited, duly reviewed and taken on record by the Board of Directors & Audit Committee of the Company.
2026-08-10 - Wockhardt Limited has informed the Exchange regarding a press release dated August 10, 2026, titled Wockhardt Antibiotic Academy, an initiative for Patient-Centric Scientific Dialogue to Tackle Multidrug Resistance .
2026-08-10 - Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on theUnaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026.
2026-08-10 - Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2026-27/027 dated 4th August, 2026, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 10th August, 2026, inter-alia, has approved the Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2026;
2026-08-07 - Pursuant to Regulation 30 read with Schedule III (Part A Para A) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the copies of Newspaper extracts regarding the addendum to the Notice of 27th Annual General Meeting of the Company.
2026-08-05 - Wockhardt Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 10, 2026
News
Recent coverage and analyst commentary for WOCKPHARMA
Loading news…
AI Stock Analyst
Wockhardt Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account